Under-prescription of novel antiplatelet drugs in patients with acute coronary syndrome and previous cardiovascular disease
| Autor: | Antonio Tello-Montoliu, Juan M. Ruiz-Nodar, Miriam Sandín-Rollán, Juan Gabriel Martínez Martínez, Miriam Quintana-Giner, Esteban Orenes-Piñero, Nuria Vicente-Ibarra, José Miguel Rivera-Caravaca, Luna Carrillo-Alemán, Vicente Pernias-Escrig, Manuel J Macías-Villanego, María Asunción Esteve-Pastor, Teresa Lozano, Francisco Marín, A Veliz-Martinez |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Ticagrelor medicine.medical_specialty Acute coronary syndrome Aftercare Coronary Disease Hemorrhage Comorbidity Kaplan-Meier Estimate Tertiary Care Centers Coronary artery disease Peripheral Arterial Disease 03 medical and health sciences 0302 clinical medicine Internal medicine Humans Medicine Prospective Studies cardiovascular diseases Acute Coronary Syndrome Prospective cohort study Stroke Proportional Hazards Models Metabolic Syndrome business.industry Smoking General Medicine medicine.disease Clopidogrel Drug Utilization Spain 030220 oncology & carcinogenesis Female 030211 gastroenterology & hepatology business Prasugrel Hydrochloride Platelet Aggregation Inhibitors Mace Follow-Up Studies medicine.drug |
| Zdroj: | Minerva Medica. 110 |
| ISSN: | 1827-1669 0026-4806 |
| Popis: | BACKGROUND Patients with acute coronary syndrome (ACS) and previous cardiovascular disease (CVD) (stroke, peripheral arterial disease [PAD] or coronary artery disease [CAD]) are at high risk of serious events and mortality. Current clinical guidelines recommend new antiplatelet drugs (NADs) for high cardiovascular risk patients with ACS; however, these drugs are underused in different scenarios. METHODS This study included 1717 ACS patients from 3 tertiary hospitals. Of them, 641 (37.33%) suffered from previous CVD: 149 patients with stroke, 154 patients with PAD and 541 patients with CAD. Bleeding, mortality and major adverse cardiac events (MACE) at 1 year of follow-up after hospital discharge were analyzed. RESULTS NADs administration during hospital stay and at discharge was less frequent in patients with previous CVDs (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|